OT::IGF::OT A phase I single-arm, multicenter pilot study aimed at validating y-OHPdG as a biomarker and testing the effects of Polyphenon E on its levels in patients with cirrhosis

NIH RePORTER · NIH · N01 · $142,069 · view on reporter.nih.gov ↗

Abstract

Hepatocellular carcinoma (HCC) is a lethal cancer with rising incidence and rates. In 2014, about 33,000 HCC diagnoses were expected, and the incidence is increasing among the most rapidly of any cancer, with an age-adjusted annual increase of 3.7% and 2.9% in men and women, respectively (3%). Tragically, HCC has a dismal 5-year survival rate of 18%, second in lethality only to pancreatic cancer. Hepatocarcinogenesis begins with changes in the liver architerure as reflected by various degrees of cirrhosis.

Key facts

NIH application ID
10329662
Project number
261201200035I-P00003-26100013-1
Recipient
NORTHWESTERN UNIVERSITY
Principal Investigator
Seema Khan
Activity code
N01
Funding institute
NIH
Fiscal year
2021
Award amount
$142,069
Award type
Project period
2020-11-06 → 2021-09-30